Vigilancia tumoral clínicamente relevante y mínimamente invasiva de gliomas difusos de la línea media pediátricos mediante biopsia líquida derivada del paciente.

Objetivo: Pediatric diffuse midline glioma (DMG) are highly malignant tumors with
poor clinical outcomes. Over 70% of patients with DMG harbor the histone 3
p.K27M (H3K27M) mutation, which correlates with a poorer clinical outcome,
and is also used as a criterion for enrollment in clinical trials. Because
complete surgical resection of DMG is not an option, biopsy at presentation
is feasible, but rebiopsy at time of progression is rare. While imaging and
clinical-based disease monitoring is the standard of care, molecular-based
longitudinal characterization of these tumors is almost nonexistent. To
overcome these hurdles, we examined whether liquid biopsy allows
measurement of disease response to precision therapy.